Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study

Salim Yusuf(Population Health Research Institute), Sonia S. Anand(Population Health Research Institute), Churchill Lukwiya Onen, Patrick Commerford, Steven Hawken(Population Health Research Institute), Paul Wangai(The Nairobi Women’s Hospital), Stephanie Ôunpuu(Population Health Research Institute), Leonelo E. Bautista, Supachai Tanomsup(Mahidol University), Zvonko Rumboldt(University of Split), Chim C. Lang(University of Dundee), Fahad Razak(Population Health Research Institute), Maria Grazia Franzosi(Goethe University Frankfurt), Arya M. Sharma(Rutgers, The State University of New Jersey)
The Lancet
November 1, 2005
10.1016/s0140-6736(05)67663-5
Cited by 2,892

Related Papers

Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k
ACC/AHA guidelines for coronary artery bypass graft surgery
|Journal of the American College of Cardiology|1999|2k
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
|The Lancet|2019|2k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k